Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Ten-year experience of the multidisciplinary Osteoncology Center.

Bongiovanni A, Recine F, Fausti V, Foca F, Casadei R, Falasconi MC, Oboldi D, Sansoni E, Fabbri L, Micheletti S, Severi S, Matteucci F, Zavoiu V, Mercatali L, Amadori D, Ibrahim T.

Support Care Cancer. 2019 Jan 16. doi: 10.1007/s00520-019-4635-5. [Epub ahead of print]

PMID:
30649614
2.

Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers.

Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, Spadazzi C, Miserocchi G, Recine F, Riva N, Nicolini S, Severi S, Martinelli G, Ibrahim T.

Dis Markers. 2018 Dec 2;2018:6878409. doi: 10.1155/2018/6878409. eCollection 2018.

3.

Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age.

Bongiovanni A, Recine F, Foca F, Fausti V, Riva N, Fabbri G, Severi S, Liverani C, De Vita A, Spadazzi C, Miserocchi G, Mercatali L, Amadori D, Ibrahim T.

Endocr Connect. 2018 Dec 1. pii: EC-18-0478.R1. doi: 10.1530/EC-18-0478. [Epub ahead of print]

4.

Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line.

Miserocchi G, De Vita A, Mercatali L, Recine F, Liverani C, Spadazzi C, Pieri F, Riva N, Bongiovanni A, Casadei R, Fausti V, Ibrahim T.

Cells. 2018 Oct 25;7(11). pii: E186. doi: 10.3390/cells7110186.

5.

Dried Blood and Serum Spots As A Useful Tool for Sample Storage to Evaluate Cancer Biomarkers.

Mercatali L, Serra P, Miserocchi G, Spadazzi C, Liverani C, De Vita A, Marisi G, Bongiovanni A, Recine F, Pangan A, Masalu N, Ibrahim T, Amadori D.

J Vis Exp. 2018 Jun 11;(136). doi: 10.3791/57113.

PMID:
29939179
6.

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma.

De Vita A, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Recine F, Bongiovanni A, Pieri F, Cavaliere D, Fausti V, Amadori D, Ibrahim T.

J Vis Exp. 2018 Apr 11;(134). doi: 10.3791/56767.

PMID:
29708525
7.

Myxofibrosarcoma primary cultures: molecular and pharmacological profile.

De Vita A, Recine F, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Casadei R, Bongiovanni A, Pieri F, Riva N, Amadori D, Ibrahim T.

Ther Adv Med Oncol. 2017 Dec;9(12):755-767. doi: 10.1177/1758834017737472. Epub 2017 Oct 28.

8.

Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents.

De Vita A, Recine F, Mercatali L, Miserocchi G, Spadazzi C, Liverani C, Bongiovanni A, Pieri F, Casadei R, Riva N, Fausti V, Amadori D, Ibrahim T.

Int J Mol Sci. 2017 Dec 8;18(12). pii: E2662. doi: 10.3390/ijms18122662.

9.

Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT: Case report and review of the literature.

Bongiovanni A, Recine F, Celli M, Marcantognini G, Foca F, Liverani C, Fausti V, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T.

Medicine (Baltimore). 2017 Nov;96(46):e8567. doi: 10.1097/MD.0000000000008567. Review.

10.

Primary leiomyosarcoma of the bone: a case report and a review of the literature.

Recine F, Bongiovanni A, Casadei R, Pieri F, Riva N, De Vita A, Mercatali L, Liverani C, Spadazzi C, Miserocchi G, Fausti V, Amadori D, Ibrahim T.

Medicine (Baltimore). 2017 Nov;96(45):e8545. doi: 10.1097/MD.0000000000008545. Review.

11.

Management and potentialities of primary cancer cultures in preclinical and translational studies.

Miserocchi G, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F, Bongiovanni A, Recine F, Amadori D, Ibrahim T.

J Transl Med. 2017 Nov 7;15(1):229. doi: 10.1186/s12967-017-1328-z. Review.

12.

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines.

Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T.

J Vis Exp. 2017 Sep 13;(127). doi: 10.3791/56311.

PMID:
28930982
13.

Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC, Chowdhury S, Niegisch G, Yu EY, Pal SK, De Giorgi U, Crabb SJ, Caubet M, Balssa L, Milowsky MI, Ladoire S, Créhange G; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Acta Oncol. 2018 Apr;57(4):491-497. doi: 10.1080/0284186X.2017.1369565. Epub 2017 Aug 30.

PMID:
28853615
14.

Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition.

Mercatali L, La Manna F, Miserocchi G, Liverani C, De Vita A, Spadazzi C, Bongiovanni A, Recine F, Amadori D, Ghetti M, Ibrahim T.

Int J Mol Sci. 2017 Jul 29;18(8). pii: E1655. doi: 10.3390/ijms18081655.

15.

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.

Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K; Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium group.

Eur Urol Focus. 2017 Jun 3. pii: S2405-4569(17)30125-6. doi: 10.1016/j.euf.2017.05.006. [Epub ahead of print]

16.

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

Colomba E, Le Teuff G, Eisen T, Stewart GD, Fife K, Larkin J, Biondo A, Pickering L, Srinivasan A, Boyle H, Derosa L, Sternberg CN, Recine F, Ralph C, Saldana C, Barthélémy P, Bernhard JC, Gurney H, Verhoest G, Vauleon E, Bigot P, Berger J, Pfister C, Gravis G, Rodier JM, Culine S, Caty A, Rolland F, Priou F, Escudier B, Albiges L.

Eur J Cancer. 2017 Jul;80:55-62. doi: 10.1016/j.ejca.2017.03.011. Epub 2017 May 23.

PMID:
28549248
17.

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G.

Ann Oncol. 2017 Nov 1;28(11):2906. doi: 10.1093/annonc/mdw551. No abstract available.

PMID:
28327895
18.

Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas.

Recine F, Bongiovanni A, Riva N, Fausti V, De Vita A, Mercatali L, Liverani C, Miserocchi G, Amadori D, Ibrahim T.

Onco Targets Ther. 2017 Feb 23;10:1155-1164. doi: 10.2147/OTT.S127955. eCollection 2017. Review.

19.

CORRECTION: Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, Snaar-Jagalska E, Ibrahim T.

Biol Open. 2017 Feb 15;6(2):309. doi: 10.1242/bio.023911. No abstract available.

20.

Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.

Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Recine F, Alva A, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY; RISC Investigators.

Cancer Med. 2017 Jan;6(1):186-194. doi: 10.1002/cam4.986. Epub 2016 Dec 20.

21.

Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18FDG-PET/CT.

Bongiovanni A, Recine F, Riva N, Foca F, Liverani C, Mercatali L, Nicolini S, Pieri F, Amadori D, Ibrahim T.

Clin Lung Cancer. 2017 Jul;18(4):415-420. doi: 10.1016/j.cllc.2016.11.004. Epub 2016 Nov 21.

PMID:
27956089
22.

Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma.

De Vita A, Miserocchi G, Recine F, Mercatali L, Pieri F, Medri L, Bongiovanni A, Cavaliere D, Liverani C, Spadazzi C, Amadori D, Ibrahim T.

Molecules. 2016 Dec 3;21(12). pii: E1662.

23.

Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, Snaar-Jagalska E, Ibrahim T.

Biol Open. 2017 Feb 15;6(2):133-140. doi: 10.1242/bio.022483. Erratum in: Biol Open. 2017 Feb 15;6(2):309.

24.

The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.

Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T.

Int J Mol Sci. 2016 Nov 1;17(11). pii: E1827.

25.

Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.

De Vita A, Mercatali L, Recine F, Pieri F, Riva N, Bongiovanni A, Liverani C, Spadazzi C, Miserocchi G, Amadori D, Ibrahim T.

Onco Targets Ther. 2016 Oct 11;9:6233-6246. eCollection 2016. Review.

26.

Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).

Bongiovanni A, Monti M, Foca F, Recine F, Riva N, Di Iorio V, Liverani C, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T.

Support Care Cancer. 2017 Jan;25(1):111-117. Epub 2016 Aug 27.

PMID:
27568305
27.

Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model.

Mercatali L, La Manna F, Groenewoud A, Casadei R, Recine F, Miserocchi G, Pieri F, Liverani C, Bongiovanni A, Spadazzi C, de Vita A, van der Pluijm G, Giorgini A, Biagini R, Amadori D, Ibrahim T, Snaar-Jagalska E.

Int J Mol Sci. 2016 Aug 22;17(8). pii: E1375. doi: 10.3390/ijms17081375.

28.

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer.

Recine F, Sternberg CN.

Transl Androl Urol. 2015 Jun;4(3):355-64. doi: 10.3978/j.issn.2223-4683.2015.04.11. Review.

29.

A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up.

Pacilio M, Ventroni G, Cassano B, Ialongo P, Lorenzon L, Di Castro E, Recine F, Sternberg CN, Mango L.

Ann Nucl Med. 2016 Feb;30(2):163-8. doi: 10.1007/s12149-015-1044-9. Epub 2015 Nov 27.

PMID:
26613714
30.

Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.

Recine F, Ceresoli GL, Baciarello G, Cerbone L, Calabrò F.

Q J Nucl Med Mol Imaging. 2015 Dec;59(4):400-10. Epub 2015 Sep 3. Review.

PMID:
26337241
31.

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.

Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Cancer. 2015 Aug 1;121(15):2586-93. doi: 10.1002/cncr.29387. Epub 2015 Apr 14.

32.

Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.

Rozzi A, Santini D, Salerno M, Bordin F, Mancuso A, Minniti G, Nardoni C, Corona M, Falbo PT, Recine F, Lanzetta G.

Med Oncol. 2013 Mar;30(1):407. doi: 10.1007/s12032-012-0407-5. Epub 2013 Jan 10.

PMID:
23307245
33.

Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.

Zivi A, Cerbone L, Recine F, Sternberg CN.

Expert Opin Drug Saf. 2012 Sep;11(5):851-9. doi: 10.1517/14740338.2012.712108. Epub 2012 Aug 4. Review.

PMID:
22861374
34.

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G.

Ann Oncol. 2012 Sep;23(9):2313-8. doi: 10.1093/annonc/mdr623. Epub 2012 Mar 5. Erratum in: Ann Oncol. 2017 Nov 1;28(11):2906.

PMID:
22396447
35.

Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey.

Mancuso A, Sacchetta S, Saletti PC, Tronconi C, Milesi L, Garassino M, Martelli O, Leone A, Zivi A, Cerbone L, Recine F, Sollami R, Labianca R, Cavalli F, Sternberg CN.

Anticancer Res. 2010 Oct;30(10):4289-95.

PMID:
21036754
36.

Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy.

Mancuso A, Sollami R, Recine F, Cerbone L, Macciomei MC, Leone A.

J Clin Oncol. 2010 Dec 20;28(36):e756-8. doi: 10.1200/JCO.2010.30.5011. Epub 2010 Sep 20. No abstract available.

PMID:
20855834

Supplemental Content

Loading ...
Support Center